301166 优宁维
已收盘 05-06 15:00:00
资讯
新帖
简况
每周股票复盘：优宁维（301166）股东户数增17.43%
证券之星 · 05-03
每周股票复盘：优宁维（301166）股东户数增17.43%
优宁维（301166）2026年一季报简析：增收不增利
证券之星 · 04-29
优宁维（301166）2026年一季报简析：增收不增利
优宁维（301166）披露2025年度募集资金存放与使用情况，4月28日股价下跌1.75%
证券之星 · 04-28
优宁维（301166）披露2025年度募集资金存放与使用情况，4月28日股价下跌1.75%
图解优宁维年报：第四季度单季净利润同比下降100.23%
证券之星 · 04-28
图解优宁维年报：第四季度单季净利润同比下降100.23%
优宁维：公司目前暂无重组事项
证券之星 · 04-22
优宁维：公司目前暂无重组事项
优宁维：公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体
证券之星 · 04-14
优宁维：公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体
股市必读：优宁维（301166）4月9日董秘有最新回复
证券之星 · 04-10
股市必读：优宁维（301166）4月9日董秘有最新回复
优宁维：与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作
证券之星 · 04-09
优宁维：与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作
优宁维（301166）披露回购公司股份进展公告，4月3日股价下跌3.83%
证券之星 · 04-03
优宁维（301166）披露回购公司股份进展公告，4月3日股价下跌3.83%
优宁维：公司自主研发主要集中于抗体及抗体相关领域
证券之星 · 04-02
优宁维：公司自主研发主要集中于抗体及抗体相关领域
优宁维：围绕两个极致战略，提升渠道和产品研发能力
证券之星 · 03-27
优宁维：围绕两个极致战略，提升渠道和产品研发能力
优宁维跌5.5% 2021年上市即巅峰超募13亿
中金财经 · 03-20
优宁维跌5.5% 2021年上市即巅峰超募13亿
免疫治疗概念震荡走强 开能健康、优宁维涨超11%
人民财讯 · 03-18
免疫治疗概念震荡走强 开能健康、优宁维涨超11%
优宁维（301166）披露参与投资设立基金进展公告，3月17日股价下跌1.79%
证券之星 · 03-17
优宁维（301166）披露参与投资设立基金进展公告，3月17日股价下跌1.79%
优宁维：公司通过股权基金投向医疗健康等领域
证券之星 · 03-17
优宁维：公司通过股权基金投向医疗健康等领域
优宁维：公司围绕抗体及相关领域寻求协同效应投资标的
证券之星 · 03-13
优宁维：公司围绕抗体及相关领域寻求协同效应投资标的
优宁维：2024年至今，公司已推出两期股份回购计划，首期已实施完毕，第二期回购计划正在实施中
证券日报 · 03-09
优宁维：2024年至今，公司已推出两期股份回购计划，首期已实施完毕，第二期回购计划正在实施中
股市必读：优宁维（301166）3月6日董秘有最新回复
证券之星 · 03-09
股市必读：优宁维（301166）3月6日董秘有最新回复
优宁维（301166）披露回购公司股份进展公告，3月2日股价下跌4.55%
证券之星 · 03-02
优宁维（301166）披露回购公司股份进展公告，3月2日股价下跌4.55%
优宁维：公司参与投资的股权投资基金投向覆盖医疗健康等领域
每日经济新闻 · 02-25
优宁维：公司参与投资的股权投资基金投向覆盖医疗健康等领域
加载更多
公司概况
公司名称：
上海优宁维生物科技股份有限公司
所属行业：
批发业
上市日期：
2021-12-28
主营业务：
上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材。
发行价格：
86.06
{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":31.02,"timestamp":1778051019000,"preClose":31.02,"halted":0,"volume":1603300,"delay":0,"changeRate":0,"floatShares":56918700,"shares":86666700,"eps":-0.2912,"marketStatus":"已收盘","change":0,"latestTime":"05-06 15:00:00","open":31,"high":31.38,"low":30.88,"amount":49955600,"amplitude":0.0161,"askPrice":31.02,"askSize":11,"bidPrice":31.01,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-0.2912,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":5,"adr":0,"adjPreClose":31.02,"symbolType":"stock","openAndCloseTimeList":[[1778031000000,1778038200000],[1778043600000,1778050800000]],"highLimit":34.12,"lowLimit":27.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86666668,"isCdr":false,"pbRate":1.35,"roa":"--","roe":"--","epsLYR":-0.26,"committee":0.541985,"marketValue":2688000000,"turnoverRate":0.0282,"status":2,"floatMarketCap":1766000000},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2632456670","title":"每周股票复盘：优宁维（301166）股东户数增17.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632456670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632456670?lang=zh_cn&edition=full","pubTime":"2026-05-03 07:16","pubTimestamp":1777763770,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，优宁维报收于31.02元，较上周的30.65元上涨1.21%。本周，优宁维4月30日盘中最高价报31.14元。股本股东变化股东户数变动截至2026年3月31日，优宁维股东户数为1.16万户，较2025年12月31日增加1726.0户，增幅达17.43%。2025年年度审计报告优宁维2025年度合并营业收入为1,083,706,364.04元，归属于母公司净利润为-22,948,743.49元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557141","title":"优宁维（301166）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557141?lang=zh_cn&edition=full","pubTime":"2026-04-29 12:31","pubTimestamp":1777437089,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期优宁维发布2026年一季报。根据财报显示，优宁维增收不增利。其中，毛利率20.31%，同比增12.11%，净利率-3.28%，同比减14.18%，销售费用、管理费用、财务费用总计4608.4万元，三费占营收比17.77%，同比减0.0%，每股净资产23.0元，同比减3.01%，每股经营性现金流-1.39元，同比减421.96%，每股收益-0.1元，同比减42.86%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-2.12%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900041038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630058517","title":"优宁维（301166）披露2025年度募集资金存放与使用情况，4月28日股价下跌1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630058517","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630058517?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:38","pubTimestamp":1777387091,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，优宁维报收于30.36元，较前一交易日下跌1.75%，最新总市值为26.31亿元。该股当日开盘30.69元，最高31.12元，最低30.14元，成交额达5010.09万元，换手率为2.87%。近日，优宁维发布《2025年度募集资金存放与使用情况专项报告》。公告显示，截至2025年12月31日，公司累计使用募集资金1,602,266,995.61元，募集资金专户余额为8,460,672.92元。本年度投入募集资金209,981,338.80元，主要用于多个募投项目。募集资金使用符合监管规定，未发现管理违规情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800065976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630316095","title":"图解优宁维年报：第四季度单季净利润同比下降100.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630316095","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630316095?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:00","pubTimestamp":1777309259,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维2025年年报显示，当年度公司主营收入10.84亿元，同比下降3.05%；归母净利润-2294.87万元，同比下降326.12%；扣非净利润-4321.38万元，同比下降185.99%；其中2025年第四季度，公司单季度主营收入3.08亿元，同比上升6.07%；单季度归母净利润-786.92万元，同比下降100.23%；单季度扣非净利润-1293.94万元，同比下降16.64%；负债率12.88%，投资收益950.86万元，财务费用-150.29万元，毛利率18.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800002796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062975","title":"优宁维：公司目前暂无重组事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629062975?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:51","pubTimestamp":1776819074,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司重组证监会批准了没？优宁维回复：投资者您好。公司目前暂无重组事项，谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200016094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627467928","title":"优宁维：公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体","url":"https://stock-news.laohu8.com/highlight/detail?id=2627467928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627467928?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:58","pubTimestamp":1776128289,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，您好公司有没有CRO业务？优宁维回复：投资者您好，公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体，主要为客户提供单/多因子相关检测分析、多色流式检测以及多色组化检测等服务。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400006327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626131020","title":"股市必读：优宁维（301166）4月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2626131020","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626131020?lang=zh_cn&edition=full","pubTime":"2026-04-10 00:53","pubTimestamp":1775753623,"startTime":"0","endTime":"0","summary":"截至2026年4月9日收盘，优宁维报收于30.5元，下跌2.93%，换手率2.39%，成交量1.36万手，成交额4176.06万元。董秘最新回复投资者： 冷总，您好公司有没有和礼来阿斯利康合作？公司与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作，双方交易规模较小，对公司业绩不构成重大影响。交易信息汇总资金流向4月9日主力资金净流出194.17万元；游资资金净流入200.5万元；散户资金净流出6.34万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000001863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626904033","title":"优宁维：与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2626904033","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626904033?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:00","pubTimestamp":1775721624,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，您好公司有没有和礼来阿斯利康合作？优宁维回复：投资者您好，公司作为生命科学一站式服务商平台，可提供生命科学所涉及的生物试剂及相关仪器、耗材和综合技术服务。公司与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作，双方交易规模较小，对公司业绩不构成重大影响。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900023353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654919","title":"优宁维（301166）披露回购公司股份进展公告，4月3日股价下跌3.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654919","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654919?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:49","pubTimestamp":1775213351,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，优宁维报收于29.86元，较前一交易日下跌3.83%，最新总市值为25.88亿元。该股当日开盘31.04元，最高31.16元，最低29.86元，成交额达6287.25万元，换手率为3.65%。近日，优宁维发布《关于回购公司股份的进展公告》。回购价格上限已由44元/股调整为43.77元/股。本次回购符合相关法律法规及公司回购方案规定。公司后续将在回购期限内继续实施回购计划，并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300036029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579927","title":"优宁维：公司自主研发主要集中于抗体及抗体相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624579927?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:51","pubTimestamp":1775116269,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司到底有没有在研发创新药，股权转让并购重组到哪一步了？优宁维回复：投资者您好，公司自主研发主要集中于抗体及抗体相关领域，目前公司主要围绕抗体上下游应用领域寻找相关标的企业，以实现与现有业务的协同发展，并通过参与投资的股权投资基金，投向覆盖医疗健康等领域。投资者可关注公司后续披露的公告及相关基金的投资进展。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200023456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622982177","title":"优宁维：围绕两个极致战略，提升渠道和产品研发能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2622982177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622982177?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:51","pubTimestamp":1774615871,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维03月26日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700046142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620873067","title":"优宁维跌5.5% 2021年上市即巅峰超募13亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2620873067","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620873067?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:23","pubTimestamp":1774002195,"startTime":"0","endTime":"0","summary":"中国经济网北京3月20日讯 优宁维 今日收报32.11元，跌幅5.50%。 2021年12月28日，优宁维在深交所创业板上市，公开发行股票2166.67万股，发行价格为86.06元/股。 优宁维首次公开发行股票募集资金总额为18.65亿元，扣除发行费用后，募集资金净额为15.96亿元。优宁维最终募集资金净额比原计划多13.12亿元。 优宁维首次公开发行股票的发行费用合计2.69亿元，国联民生获得承销及保荐费用2.48亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260320/32085393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620283483","title":"免疫治疗概念震荡走强 开能健康、优宁维涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620283483","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620283483?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:44","pubTimestamp":1773801872,"startTime":"0","endTime":"0","summary":"人民财讯3月18日电，免疫治疗概念震荡走强，开能健康、优宁维涨超11%，中源协和、荣昌生物、济民健康、益诺思等涨幅居前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675702952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0224","BK0150","300272","BK0020","BK0042","BK0135","BK0046","301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620754094","title":"优宁维（301166）披露参与投资设立基金进展公告，3月17日股价下跌1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620754094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620754094?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:55","pubTimestamp":1773759314,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，优宁维报收于32.28元，较前一交易日下跌1.79%，最新总市值为27.98亿元。近日，上海优宁维生物科技股份有限公司发布《关于参与投资设立基金的进展公告》。公告显示，公司于2022年11月10日与多方签署协议，共同设立上海引领接力行健私募基金合伙企业。基金已办理完毕最新工商变更登记，取得新的营业执照，出资额为人民币120010万元，执行事务合伙人为上海孚腾私募基金管理有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427873","title":"优宁维：公司通过股权基金投向医疗健康等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427873?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:51","pubTimestamp":1773751903,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)03月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好公司产品有涉足智能医疗领域吗？优宁维回复：投资者您好，公司围绕两个极致战略，通过持续的投入不断提升产品丰富度，通过第三方品牌加自主品牌的布局，为客户提供一站式服务；同时公司围绕抗体及相关领域，寻求与公司产品和业务具有协同效应的投资标的，并通过投资的股权基金，投向覆盖医疗健康等领域。投资者可关注公司后续披露的公告及相关基金的投资进展。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197206","title":"优宁维：公司围绕抗体及相关领域寻求协同效应投资标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619197206?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:52","pubTimestamp":1773406324,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)03月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好脑机接口晒道潜力无限政策扶持公司为何不收购投资相关产业链企业来进入享受时代风口红利？优宁维回复：投资者您好，公司围绕抗体及相关领域，寻求与公司产品和业务具有协同效应的投资标的，适时通过外延并购投资等方式，加快公司业务发展，提升公司持续经营能力。此外公司投资的股权投资基金，投向覆盖医疗健康等领域，投资者可关注相关基金的投资进展。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300038442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618277356","title":"优宁维：2024年至今，公司已推出两期股份回购计划，首期已实施完毕，第二期回购计划正在实施中","url":"https://stock-news.laohu8.com/highlight/detail?id=2618277356","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618277356?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:12","pubTimestamp":1773065520,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月9日，优宁维在互动平台回答投资者提问时表示，近年来受市场需求尚未明显复苏影响，公司整体收入未达预期，自主品牌业务虽保持较快增长但业务占比较低，毛利率仍处于过往较低水平；同时公司在销售费用与研发费用方面持续维持较高比例投入，以推动产品结构转型，力争实现盈利能力和销售业绩的双增长。2024年至今，公司已推出两期股份回购计划，首期已实施完毕，第二期回购计划正在实施中，计划用于减少注册资本，最新的回购情况投资者可关注公司发布的回购进展公告。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-09/doc-inhqmcpp6853671.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-09/doc-inhqmcpp6853671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618669574","title":"股市必读：优宁维（301166）3月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2618669574","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618669574?lang=zh_cn&edition=full","pubTime":"2026-03-09 02:14","pubTimestamp":1772993653,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，优宁维报收于32.9元，上涨3.46%，换手率2.02%，成交量1.15万手，成交额3735.71万元。董秘最新回复投资者： 冷总，公司每股净资产这么高建议公司今年高送转增强流动性！交易信息汇总资金流向3月6日主力资金净流出213.81万元；游资资金净流出119.96万元；散户资金净流入333.77万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900000983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616359398","title":"优宁维（301166）披露回购公司股份进展公告，3月2日股价下跌4.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616359398","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616359398?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:27","pubTimestamp":1772465232,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，优宁维报收于31.87元，较前一交易日下跌4.55%，最新总市值为27.62亿元。该股当日开盘32.93元，最高33.09元，最低31.52元，成交额达5840.33万元，换手率为3.19%。优宁维于近日披露《关于回购公司股份的进展公告》。本次回购符合相关法律法规及公司回购方案规定。公司后续将根据市场情况继续实施回购计划，并履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614805640","title":"优宁维：公司参与投资的股权投资基金投向覆盖医疗健康等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2614805640","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614805640?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:15","pubTimestamp":1772025300,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：公司有涉足布局投资脑机接口等未来产业吗？优宁维（301166.SZ）2月25日在投资者互动平台表示，公司参与投资的股权投资基金投向覆盖医疗健康等领域，投资者可关注相关基金的投资进展。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-25/doc-inhnzvzh5036942.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-25/doc-inhnzvzh5036942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","XBI","BK4585","159760","301166","XLV","BK0250","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778069146887,"stockEarnings":[{"period":"1week","weight":0.0285},{"period":"1month","weight":0.0289},{"period":"3month","weight":-0.0473},{"period":"6month","weight":-0.033},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0451}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"11627人(较上一季度增加17.43%)","perCapita":"4895股","listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","registeredCapital":"8666万元","survey":" 上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材。","listedPrice":86.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}